Clinically significant CYP2C19 genotypes in patients with myocardial infarction in the northern region of Russia

Aim. To determine the associations of allelic variants of the CYP2C19 gene with coronary atherosclerosis and ischemic events in patients with myocardial infarction (MI) living in the Khanty-Mansi Autonomous Okrug — Yugra.

Material and methods. This prospective observational study included 203 patients with acute MI who underwent percutaneous coronary intervention. Patients also underwent genetic testing using real-time polymerase chain reaction to determine allelic variants of the CYP2C19 gene. Using biostatistical analysis methods, associations were established between the genotypes of patients with MI, their clinical characteristics and major ischemic events over 7-year follow-up.

Results. Significant associations were identified between allelic variants of CYP2C19*2 (*1/*2 and *2/*2) and smoking, right ventricular volume and glomerular filtration rate (GFR). The presence of the allelic variant CYP2C19*3 (*3/*3) was associated with GFR ³90 ml/min/1,73 m² and impaired glucose tolerance. A significant association was established between the CYP2C19*17 alleles (*1/*17, *17/*17) with coronary atherosclerosis, smoking, levels of troponin T, aspartate aminotransferase, total cholesterol, left ventricular posterior wall thickness, and a history of myocardial infarction. Data from multivariate analysis showed a clear association of allelic variants of CYP2C19*2 (*1/*2 and *2/*2) with the composite endpoint of 7-year follow-up (death, recurrent myocardial infarction, stent/bypass thrombosis, myocardial revascularization). A significant influence of CYP2C19*17 genotypes (*1/*17 and *17/*17) on myocardial revascularization in patients in the post-infarction period was also determined.

Conclusion. CYP2C19*2 genotypes (*1/*2 and *2/*2) in MI patients living in Khanty-Mansi Autonomous Okrug — Yugra are clearly associated with ischemic events during a 7-year follow-up. CYP2C19*17 genotypes (*1/*17 and *17/*17) are clearly associated with coronary atherosclerosis and myocardial revascularization in the long-term post-infarction period.

1. Nikolaev KY, Urvantseva IA, Batueva KYu, et al. Regional aspects of associations of the CYP2C19 gene polymorphism with coronary atherosclerosis in acute coronary syndrome. Russian Journal of Cardiology. 2018;(10):28-32. (In Russ.) doi:10.15829/1560-4071-2018-10-28-32.

2. Zelenskaya EM, Lifshits GI, Nikolaev KY et al. The Frequency of the Minor Polymorphisms in the CYP2C19, VEGFR-2 Genes, and Clinical Outcomes in Russian and Buryat Patients with Acute Coronary Syndrome. Genetic Testing and Molecular Biomarkers. 2020;24(6):338-42. doi:10.1089/gtmb.2019.0216.

3. Sibbing D, Aradi D, Alexopoulos D, et al. Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. Journal of American College of Cardiology: Cardiovascular Interventions. 2019;12(16):1521-37. doi:10.1016/j.jcin.2019.03.034.

4. Martínez-Quintana E, Rodríguez-González F, Medina-Gil JM, et al. CYP2C19 activity and cardiovascular risk factors in patients with an acute coronary syndrome. Medicina Clinica (Barc). 2017;149(6):235-9. doi:10.1016/j.medcli.2017.02.035.

5. Kurupanova AS, Lareva NV. CYP2C19*2 gene polymorphism and association with risk factors, historical data, clinical events and outcomes in men and women with ST-elevation acute coronary syndrome. Eurasian Cardiology Journal. 2019;(2S):212-3. (In Russ.)

6. Teixeira R, Monteiro P, Marques G, et al. CYP2C19*2 and prognosis after an acute coronary syndrome: Insights from a Portuguese center. Portuguese Journal of Cardiology. 2012;31(4):265-73. doi:10.1016/j.repc.2012.02.001.

7. Yi S, Pan Y, Zhang Y, et al. Association of different CYP2C19 genotypes with clopidogrel efficacy and adverse cardiovascular events during hospitalization in patients with ACS. Acta Medica Mediterranea. 2020;36:89-93. doi:10.19193/0393-6384_2020_1_12.

8. Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. Journal of American Medical Association. 2010;304(16):1821-30. doi:10.1001/jama.2010.1543.